Phase I Study of Ad5 [E1-, E2b-]-HER2/Neu Vaccine (ETBX-021) in Subjects With Unresectable Locally Advanced or Metastatic HER2-Low-Expressing (IHC 1+/2+) Breast Cancer

Trial Profile

Phase I Study of Ad5 [E1-, E2b-]-HER2/Neu Vaccine (ETBX-021) in Subjects With Unresectable Locally Advanced or Metastatic HER2-Low-Expressing (IHC 1+/2+) Breast Cancer

Recruiting
Phase of Trial: Phase I

Latest Information Update: 28 Sep 2017

At a glance

  • Drugs ETBX 021 (Primary)
  • Indications Advanced breast cancer; Male breast cancer
  • Focus Adverse reactions
  • Sponsors NantBioScience
  • Most Recent Events

    • 19 Dec 2016 Status changed from not yet recruiting to recruiting.
    • 03 Oct 2016 Planned initiation date changed from 1 Jul 2016 to 1 Oct 2016.
    • 28 Apr 2016 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top